Titan Pharmaceuticals, Inc. (NasdaqCM: TTNP) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Titan Pharmaceuticals, Inc. (the “Company”) (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company’s shareholders.